10-Q: Coherus Oncology Navigates Strategic Shift, LOQTORZI Sales Rise

Coherus Oncology reports Q3 2025 results, highlighting LOQTORZI revenue growth and the completion of its biosimilar divestiture strategy, alongside ongoing operating losses.

Summary

• Net loss from continuing operations was $(44.5) million for the three months ended September 30, 2025, and $(136.8) million for the nine months ended September 30, 2025.
• The company reported a net loss of $(35.5) million for Q3 2025, but a net income of $205.7 million for the nine months ended September 30, 2025, primarily driven by the gain on the UDENYCA divestiture.
• LOQTORZI net revenue significantly increased to $11.2 million for Q3 2025, up from $5.8 million in Q3 2024, and to $28.5 million for the nine months ended September 30, 2025, up from $11.6 million in the prior year period, driven by volume growth.
• The divestiture of the UDENYCA business was completed on April 11, 2025, for upfront cash consideration of $483.4 million, marking the completion of the company's biosimilar strategic shift.
• As of September 30, 2025, cash, cash equivalents, and marketable securities totaled $191.7 million, with an accumulated deficit of $1.3 billion.
• A material weakness in internal control over financial reporting related to inventory account reconciliations was identified in 2024, with remediation efforts ongoing, though the specific control was decommissioned with the UDENYCA sale.
• On October 21, 2025, the company completed a private placement, selling 4,634,995 shares of common stock and warrants for $8.0 million.

Sentiment

Score: 6

Explanation: The strong growth of LOQTORZI revenue and the successful divestiture of biosimilar assets are positive, providing a clearer strategic focus and significant cash infusion. However, the company still faces substantial operating losses from continuing operations, an accumulated deficit, and significant R&D expenses for pipeline candidates, alongside competitive and regulatory risks. The capital raise and ongoing ATM facility indicate a continued need for funding.

Positives

• LOQTORZI net revenue increased by 91.5% to $11.2 million in Q3 2025 compared to $5.8 million in Q3 2024, and by 145.3% to $28.5 million in 9M 2025 compared to $11.6 million in 9M 2024, indicating strong commercial traction.
• The successful divestiture of the UDENYCA business for $483.4 million in cash completed the strategic shift away from biosimilars to innovative oncology.
• The company is eligible to receive two additional $37.5 million earnout payments from the UDENYCA sale, contingent on net sales thresholds.
• Nasdaq compliance was regained on September 5, 2025, as the common stock bid price closed above the $1.00 minimum requirement.
• Total stockholders' equity turned positive to $87.8 million as of September 30, 2025, from a deficit of $(132.0) million at December 31, 2024.
• Net income for the nine months ended September 30, 2025, was $205.7 million, primarily due to the $338.7 million gain on the UDENYCA Sale.
• Gross margin for continuing operations improved to 68% in Q3 2025 and 67% in 9M 2025.
• Selling, general and administrative expenses from continuing operations decreased by $3.2 million in Q3 2025 and $18.9 million in 9M 2025, driven by lower headcount and professional fees.
• Interest expense from continuing operations decreased by $0.5 million in Q3 2025 and $2.1 million in 9M 2025, primarily due to the repayment of the 2027 Term Loans.

Negatives

• The company reported a net loss from continuing operations of $(44.5) million for Q3 2025 and $(136.8) million for 9M 2025, indicating ongoing operational unprofitability.
• An accumulated deficit of $1.3 billion as of September 30, 2025, reflects a history of significant operating losses.
• Research and development expenses from continuing operations increased by $5.2 million in Q3 2025 and $6.8 million in 9M 2025, driven by increased investment in CHS-114 and casdozokitug development.
• The company remains highly dependent on the commercial success of its single approved product, LOQTORZI, for continuing operations revenue.
• There is no guarantee that the company will receive the two contingent $37.5 million earnout payments from the UDENYCA sale.
• A material weakness in internal control over financial reporting was identified in 2024, which, despite remediation efforts, indicates a control deficiency.
• Net cash used in operating activities was $(118.8) million for the nine months ended September 30, 2025.

Risks

• The company has a limited history of profitability and may not achieve it again, especially after the UDENYCA divestiture, as innovative oncology product development is expensive and risky.
• The commercial success of LOQTORZI and any future products depends on market acceptance, adoption by prescribing physicians, healthcare providers, and patients, as well as adequate third-party payer coverage and reimbursement.
• Reliance on collaborators, such as Junshi Biosciences, for LOQTORZI's development, regulatory, and manufacturing expertise poses risks if these third parties fail to meet their obligations.
• LOQTORZI and product candidates remain subject to ongoing regulatory scrutiny, with potential for delays, restrictions on use, or even withdrawal of regulatory approval.
• Disruptions at the FDA and other government agencies due to funding shortages, staffing limitations, government shutdowns, or global health concerns could hinder timely approvals.
• The company faces significant competition from numerous established and emerging immuno-oncology biologics, including Keytruda, Opdivo, Tecentriq, Imfinzi, Bavencio, Libtayo, Jemperli, TEVIMBRA, Penpulimab-kcqx, and camrelizumab.
• Healthcare reform measures, including the Inflation Reduction Act of 2022 (IRA) and the One Big Beautiful Bill Act (OBBBA), may increase costs, affect pricing, and materially adversely affect the business.
• High dependence on key executives and personnel, including President and CEO Dennis M. Lanfear; the inability to retain or recruit additional management, clinical, and scientific personnel could harm the business.
• Reliance on third-party contract research organizations (CROs) and contract manufacturing organizations (CMOs) for studies and supply carries risks of contractual breaches, missed deadlines, quality issues, and regulatory non-compliance.
• Manufacturing risks include product loss due to contamination or equipment failure, supply chain disruptions, and the risk of inaccurately forecasting sales, potentially leading to inventory write-downs or charges related to firm purchase commitments.
• Product candidates may cause undesirable side effects or have other properties that could delay or prevent regulatory approval, limit commercial labeling, or result in significant negative consequences following marketing approval.
• The company risks infringing or being alleged to infringe intellectual property rights of third parties, which could lead to costly litigation, substantial damages, and prevent or delay commercialization efforts.
• There is no guarantee that the company will receive either of the two $37.5 million Earnout Payments under the UDENYCA Purchase Agreement.
• Risks and uncertainties are associated with the UDENYCA Transition Service Agreement (TSA), including the need to expend management time, provide significant support services, exposure to Intas's financial status, and potential unanticipated costs.
• The potential for 'submarine patents' (patents issuing from previously unpublished applications) to competitors could significantly alter launch timing expectations, reduce projected market size, or block market entry.
• The company may not be able to protect its intellectual property rights throughout the world, as filing and enforcing patents globally is expensive and laws vary.
• Adverse developments affecting the financial services industry, such as liquidity issues or defaults by financial institutions, could adversely affect the company's business operations and access to cash.
• Continued inflation may negatively impact product demand, costs for labor and materials, margins, and interest rates on variable rate indebtedness.
• Failure to comply with environmental, health, and safety laws and regulations could result in fines, penalties, or significant costs.
• Information technology systems, or those of third-party contractors, may fail or suffer security breaches, with geopolitical tensions increasing the risk of cyberattacks, leading to data loss, liabilities, and reputational damage.
• Compliance with evolving global privacy, data protection, and information security laws (e.g., GDPR, CCPA) could result in additional costs, liabilities, or inhibit data collection and processing.

Future Outlook

The company expects net revenue and cost of goods sold from continuing operations in 2025 to be higher than in 2024 due to continued growth of LOQTORZI. Research and development expenses are also projected to be higher in 2025 compared to 2024 due to ongoing investments in the immuno-oncology pipeline. Conversely, selling, general and administrative expenses and interest expense from continuing operations are expected to be lower in 2025 than in 2024 due to decreased operating costs, headcount, and debt repayments. Management believes that available cash, cash equivalents, marketable securities, product sales, and ATM Offering proceeds will be sufficient to fund planned expenditures and meet obligations for at least the next twelve months, but acknowledges that additional funds may be needed sooner than anticipated.

Management Comments

• Our strategy is to grow sales of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both our pipeline candidates as well as through our partners, driving sales multiples and synergies from proprietary combinations.
• We believe that our available cash, cash equivalents and marketable securities, product sales, and ATM Offering proceeds received to date will be sufficient to fund our planned expenditures and meet our obligations for at least the twelve months following our financial statement issuance date.

Industry Context

Coherus Oncology operates in the highly competitive and rapidly evolving immuno-oncology sector of the pharmaceutical industry. The company's strategic shift from biosimilars to a focused innovative oncology model aligns with a broader industry trend towards higher-value, novel therapies, though this also entails increased research and development risks. LOQTORZI, as an anti-PD-1 inhibitor, competes in a crowded market against established products from major pharmaceutical players. The company's pipeline candidates, casdozokitug and CHS-114, are also entering competitive development landscapes. The industry faces significant regulatory scrutiny, pricing pressures from healthcare reform measures like the IRA and OBBBA, and challenges in securing adequate third-party coverage and reimbursement, which can impact market penetration and profitability.

Comparison to Industry Standards

• LOQTORZI competes with several FDA-approved anti-PD-1 or PD-L1 antibody drugs, including Keytruda (pembrolizumab) from Merck & Company, Inc., Opdivo (nivolumab) from Bristol-Myers Squibb Company, Tecentriq (atezolizumab) from Genentech, Inc., Imfinzi (durvalumab) from AstraZeneca plc, Bavencio (avelumab) from EMD Serono Inc. and Pfizer Inc., Libtayo (cemiplimab-rwlc) from Regeneron Pharmaceuticals, Inc., Jemperli (dostarlimab-gxly) from GlaxoSmithKline plc, and TEVIMBRA (tislelizumab-jsgr) from BeiGene, Ltd.
• Penpulimab-kcqx from Akeso Biopharma Co., Ltd. also received FDA approval in April 2025 for the treatment of NPC, adding to the competitive landscape for LOQTORZI.
• NCCN's update to clinical practice guidelines for NPC, specifying LOQTORZI as the *only preferred* Category 1 first-line treatment option in combination with cisplatin and gemcitabine, positions it favorably against other treatments in this specific indication.
• Casdozokitug, targeting IL-27, is noted as the only antagonist antibody in development known to the company for this target, potentially offering a unique mechanism of action compared to other immuno-oncology products.
• CHS-114, targeting CCR8, faces competition from programs in development by Bristol-Myers Squibb Company, Gilead Sciences, Inc. / Jounce, Shionogi, AbbVie Inc., Bayer AG, F. Hoffmann-La Roche Ltd, Amgen Inc., LaNova Medicines, and Nanjing Immunophage Biotech Co., Ltd.
• Many of the company's competitors possess substantially greater financial, technical, and other resources, including larger research and development, marketing, and manufacturing organizations, which provides them a competitive advantage in product development, regulatory approval, and commercialization.

Legal Proceedings

• The company is a party to various legal proceedings and claims that arise in the ordinary, routine course of business, with an accrual of $6.4 million as of September 30, 2025.
• In late April 2022, the company received a demand letter from Zinc Health Services, LLC asserting claims of approximately $14.0 million related to certain sales of UDENYCA from October 2020 through December 2021. No legal proceeding has been filed, and the final resolution is uncertain; the company intends to defend any legal proceeding.

Stakeholder Impact

• Shareholders face potential dilution from future equity raises (ATM, private placement) and stock price volatility, but also potential appreciation if LOQTORZI growth continues and pipeline progresses.
• Employees have experienced a decrease of approximately 68 full-time equivalents since December 31, 2024, due to divestitures and reductions in force, which could impact morale and productivity.
• Customers and patients benefit from the continued availability of LOQTORZI for NPC and the ongoing development of new oncology candidates.
• Creditors are impacted by the company's debt obligations (2029 Term Loan, remaining 2026 Convertible Notes, Revenue Purchase and Sale Agreement liability) and the need for compliance with associated covenants.
• Partners, such as Junshi Biosciences and Apotex, are involved in ongoing collaborations for LOQTORZI, while Intas Pharmaceuticals Ltd. is tied to potential earnout payments from the UDENYCA sale and the Transition Service Agreement obligations.

Next Steps

• Grow sales of LOQTORZI in nasopharyngeal carcinoma (NPC).
• Advance the development of new indications for LOQTORZI in combination with pipeline candidates and through partners.
• Continue the post-marketing commitment study for LOQTORZI in advanced NPC (clinicaltrials.gov identifier# NCT06457503).
• Junshi Biosciences is enrolling a multiregional Phase 3 clinical study evaluating LOQTORZI with its investigational anti-BTLA antibody in LS-SCLC (clinicaltrials.gov identifier# NCT06095583).
• INOVIO Pharmaceuticals, Inc. plans a randomized Phase 3 study of INO-3112 and toripalimab in locally advanced, high risk HPV16/18+ oropharyngeal squamous cell carcinoma.
• Cancer Research Institute is evaluating toripalimab in combination with ENB Therapeutics' investigational agent ENB-003 in its Phase 2 trial (IPROC) (clinicaltrials.gov identifier# NCT04918186).
• STORM Therapeutics, Ltd. is evaluating its METTL3 inhibitor STC-15 in combination with LOQTORZI in a Phase 1b/2 study (clinicaltrials.gov identifier# NCT06975293) for NSCLC and HNSCC, with plans for melanoma and endometrial cancer.
• Continue evaluating Casdozokitug (CHS-388) in an ongoing randomized Phase 2 clinical study in HCC in combination with toripalimab and bevacizumab (clinicaltrials.gov identifier# NCT06679985).
• Continue evaluating CHS-114 in combination with toripalimab in a Phase 1b clinical study in second-line HNSCC (clinicaltrials.gov identifier# NCT05635643).
• Continue an ongoing Phase 1b/2a clinical study of CHS-114 in combination with toripalimab and/or other treatments in participants with advanced solid tumors (clinicaltrials.gov identifier# NCT06657144).
• Remediate the material weakness in internal control over financial reporting through additional training and enhancement of documentation and retention procedures.
• Potentially receive two $37.5 million Earnout Payments from the UDENYCA sale if net sales thresholds are met by September 30, 2026, and March 31, 2027, respectively.
• May utilize the ATM Offering to sell common stock to raise additional capital.
• May need to raise additional funds in the future to meet operational needs and capital requirements for product development and commercialization.

Key Dates

Recommendation

Coherus Oncology is undergoing a significant strategic transformation, divesting its biosimilar assets to focus on innovative oncology with LOQTORZI. While LOQTORZI shows promising revenue growth and NCCN guideline recognition, the company still faces substantial operating losses from its continuing operations and has a large accumulated deficit. The cash infusion from the UDENYCA sale provides liquidity, but the long-term profitability hinges on the successful development and commercialization of its pipeline candidates, which is a high-risk, capital-intensive endeavor. The recent private placement and ongoing ATM offering indicate a continued need for capital. Investors should hold to observe the execution of the oncology strategy, the trajectory of LOQTORZI sales, and the progress of pipeline assets, as the company transitions to a more focused, but still speculative, business model.

Keywords

Oncology, LOQTORZI, PD-1 inhibitor, Nasopharyngeal Carcinoma, Biosimilars, UDENYCA, CHS-388, Casdozokitug, CHS-114, CCR8, IL-27, Clinical Trials, FDA Approval, Pharmaceutical, Biotechnology, SEC Filing, 10-Q, Financial Results, Divestiture, Capital Raise, Corporate Governance, Risk Management, Immuno-oncology